NO2516457T3 - - Google Patents

Info

Publication number
NO2516457T3
NO2516457T3 NO10791039A NO10791039A NO2516457T3 NO 2516457 T3 NO2516457 T3 NO 2516457T3 NO 10791039 A NO10791039 A NO 10791039A NO 10791039 A NO10791039 A NO 10791039A NO 2516457 T3 NO2516457 T3 NO 2516457T3
Authority
NO
Norway
Application number
NO10791039A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43601078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2516457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2516457T3 publication Critical patent/NO2516457T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
NO10791039A 2009-12-21 2010-12-17 NO2516457T3 (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28856209P 2009-12-21 2009-12-21
PCT/US2010/060925 WO2011084664A1 (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE

Publications (1)

Publication Number Publication Date
NO2516457T3 true NO2516457T3 (en:Method) 2018-08-11

Family

ID=43601078

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10791039A NO2516457T3 (en:Method) 2009-12-21 2010-12-17

Country Status (27)

Country Link
US (9) US8658154B2 (en:Method)
EP (4) EP3336102A3 (en:Method)
JP (4) JP5595517B2 (en:Method)
KR (4) KR102092744B1 (en:Method)
CN (2) CN104232589B (en:Method)
AU (3) AU2010339863B2 (en:Method)
CA (2) CA3000246C (en:Method)
CY (1) CY1120316T1 (en:Method)
DK (2) DK2516457T3 (en:Method)
ES (2) ES3062012T3 (en:Method)
FI (1) FI3498730T3 (en:Method)
HK (1) HK1257001A1 (en:Method)
HR (2) HRP20260349T1 (en:Method)
HU (1) HUE038684T2 (en:Method)
IL (4) IL220365A (en:Method)
LT (2) LT2516457T (en:Method)
MY (1) MY156743A (en:Method)
NO (1) NO2516457T3 (en:Method)
PL (2) PL3498730T3 (en:Method)
PT (2) PT2516457T (en:Method)
RS (2) RS67844B1 (en:Method)
RU (1) RU2549695C2 (en:Method)
SG (3) SG10201408415PA (en:Method)
SI (2) SI2516457T1 (en:Method)
SM (2) SMT201800296T1 (en:Method)
TR (1) TR201808011T4 (en:Method)
WO (1) WO2011084664A1 (en:Method)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2516457T3 (en:Method) 2009-12-21 2018-08-11
PL2818478T3 (pl) 2011-10-28 2017-09-29 Regeneron Pharmaceuticals, Inc. Humanizowane il-6 i receptor il-6
JP2014532399A (ja) * 2011-11-01 2014-12-08 ロシュ グリクアート アーゲー インビボａｄｃｃモデル
ES2884598T3 (es) * 2012-11-05 2021-12-10 Regeneron Pharma Animales no humanos modificados genéticamente y métodos de uso de los mismos
ES2844174T3 (es) 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
AU2014337526B2 (en) 2013-10-15 2020-09-10 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
CN106255410B (zh) * 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
RU2700484C2 (ru) * 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
AU2015266841C1 (en) 2014-05-30 2018-06-07 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase IV (DPP4) animals
EP3808775B1 (en) * 2014-12-09 2024-04-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
PT3282835T (pt) * 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
WO2016175285A1 (ja) * 2015-04-30 2016-11-03 株式会社特殊免疫研究所 ヒト特定分子およびヒトＦｃγ受容体ファミリーを発現するトランスジェニック非ヒト動物
US20170332610A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
EP3861854B1 (en) * 2018-09-27 2025-01-22 Central Institute for Experimental Medicine and Life Science Immunodeficient mouse
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
US20220192166A1 (en) * 2019-03-28 2022-06-23 Central Institute For Experimental Animals Immunodeficient rodent
AU2021400584A1 (en) * 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
EP4287828A4 (en) * 2021-02-02 2025-01-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011490A1 (en) * 1988-05-27 1989-11-30 Schering Biotech Corporation HUMAN Fcgamma RECEPTOR III
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5258359A (en) * 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US5899312A (en) * 1997-07-22 1999-05-04 Lucent Technologies Inc Anti-fraud string grabbing device
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US7413031B2 (en) 2000-07-18 2008-08-19 The Charles Machine Works, Inc. Apparatus and method for maintaining control of a drilling machine
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
FR2822161B1 (fr) 2001-03-15 2003-09-19 Genoway Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
JP4653915B2 (ja) * 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003233246B2 (en) 2002-06-07 2008-04-10 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd FcyRIIa transgenic animal model for autoimmune disease
JP2004147535A (ja) * 2002-10-29 2004-05-27 Japan Science & Technology Agency ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物
JP2006517096A (ja) 2002-12-16 2006-07-20 ジェネンテック・インコーポレーテッド ヒトｃｄ２０を発現するトランスジェニックマウス
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
US20070148170A1 (en) * 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
EP1706424B1 (en) * 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
JP5401314B2 (ja) * 2006-09-08 2014-01-29 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
BRPI0813985B1 (pt) 2007-07-31 2022-05-10 Regeneron Pharmaceuticals, Inc Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
AU2008335178A1 (en) * 2007-12-10 2009-06-18 Ablexis Llc Methods for sequential replacement of targeted region by homologous recombination
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
WO2010010549A2 (en) * 2008-07-23 2010-01-28 Rappaport Family Institute For Research In The Medical Sciences Methods of altering peripheral b cell populations and uses thereof
NO2516457T3 (en:Method) 2009-12-21 2018-08-11
US8883496B2 (en) * 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice

Also Published As

Publication number Publication date
US20240424145A1 (en) 2024-12-26
KR20190045404A (ko) 2019-05-02
JP2014132909A (ja) 2014-07-24
IL242719A (en) 2017-09-28
SMT201800296T1 (it) 2018-07-17
RU2012131296A (ru) 2014-01-27
MY156743A (en) 2016-03-31
KR102092744B1 (ko) 2020-03-24
KR20200033981A (ko) 2020-03-30
US20200061213A1 (en) 2020-02-27
US20150313195A1 (en) 2015-11-05
EP4706388A2 (en) 2026-03-11
SI3498730T1 (sl) 2026-03-31
US8658853B2 (en) 2014-02-25
HRP20180911T1 (hr) 2018-07-13
US12036288B2 (en) 2024-07-16
SG10202011814TA (en) 2021-01-28
IL220365A (en) 2016-11-30
US20140154701A1 (en) 2014-06-05
AU2010339863A1 (en) 2012-07-12
JP5891259B2 (ja) 2016-03-22
CA2784953C (en) 2018-05-22
KR101862277B1 (ko) 2018-06-01
KR20180058860A (ko) 2018-06-01
US8658154B2 (en) 2014-02-25
CA3000246A1 (en) 2011-07-14
EP3498730A1 (en) 2019-06-19
RS67844B1 (sr) 2026-03-31
EP2516457A1 (en) 2012-10-31
KR20120102138A (ko) 2012-09-17
HUE038684T2 (hu) 2018-11-28
CY1120316T1 (el) 2019-07-10
CN102762590A (zh) 2012-10-31
AU2010339863B2 (en) 2014-07-17
EP2516457B9 (en) 2021-09-29
US20120260357A1 (en) 2012-10-11
US20140157445A1 (en) 2014-06-05
IL261257A (en) 2018-10-31
CA2784953A1 (en) 2011-07-14
RU2549695C2 (ru) 2015-04-27
US20110154512A1 (en) 2011-06-23
AU2014210646A1 (en) 2014-08-28
SG10201408415PA (en) 2015-01-29
ES2671188T3 (es) 2018-06-05
AU2014210646B2 (en) 2016-06-23
SI2516457T1 (en) 2018-08-31
CN104232589A (zh) 2014-12-24
RS57280B1 (sr) 2018-08-31
JP5595517B2 (ja) 2014-09-24
CA3000246C (en) 2021-05-25
EP3498730B1 (en) 2026-01-28
AU2014210645A1 (en) 2014-08-28
DK2516457T3 (en) 2018-06-18
JP6073840B2 (ja) 2017-02-01
HK1257001A1 (en) 2019-10-11
US20210346522A1 (en) 2021-11-11
DK3498730T3 (da) 2026-02-23
FI3498730T3 (fi) 2026-03-12
AU2014210645B2 (en) 2016-05-19
PL2516457T3 (pl) 2018-08-31
SG181690A1 (en) 2012-07-30
HRP20260349T1 (hr) 2026-04-24
US9089599B2 (en) 2015-07-28
US9056130B2 (en) 2015-06-16
CN102762590B (zh) 2015-11-25
CN104232589B (zh) 2018-04-27
US20180015185A1 (en) 2018-01-18
EP3336102A2 (en) 2018-06-20
US10426848B2 (en) 2019-10-01
PL3498730T3 (pl) 2026-04-07
US11020495B2 (en) 2021-06-01
IL220365A0 (en) 2012-08-30
PT3498730T (pt) 2026-02-18
JP2016093201A (ja) 2016-05-26
SMT202600074T1 (it) 2026-03-09
WO2011084664A1 (en) 2011-07-14
KR101973524B1 (ko) 2019-09-02
KR102178064B1 (ko) 2020-11-12
PT2516457T (pt) 2018-06-12
LT3498730T (lt) 2026-03-25
JP2014209923A (ja) 2014-11-13
JP2013514778A (ja) 2013-05-02
TR201808011T4 (tr) 2018-06-21
US9687566B2 (en) 2017-06-27
IL261257B (en) 2019-12-31
IL271083A (en) 2020-01-30
LT2516457T (lt) 2018-06-11
EP2516457B1 (en) 2018-03-14
EP3336102A3 (en) 2018-08-01
ES3062012T3 (en) 2026-04-08

Similar Documents

Publication Publication Date Title
BRPI0925311A2 (en:Method)
BR112012008195A2 (en:Method)
BR112012003062A2 (en:Method)
BRPI0924307A2 (en:Method)
BR112012012396A2 (en:Method)
BR122021004633A2 (en:Method)
BR112012003080A2 (en:Method)
BR112012012487A2 (en:Method)
BR112012003853A2 (en:Method)
BRPI0924534A2 (en:Method)
BR112012009797A2 (en:Method)
BR112012009446A2 (en:Method)
BR112012001263A2 (en:Method)
BR112012007656A2 (en:Method)
BR112012014856A2 (en:Method)
BR112012000159A2 (en:Method)
BR112012002627A2 (en:Method)
BR112012007654A2 (en:Method)
BR112012005951A2 (en:Method)
BR112012007672A2 (en:Method)
BR112012000156A2 (en:Method)
BR112012007671A2 (en:Method)
BRPI0925022A2 (en:Method)
BRPI0924617A2 (en:Method)
BR112012016234A2 (en:Method)